Attana receives contract research order from global pharma company
Attana has received a new order for a contract research project. The order has been placed from an existing customer with main offices in Europe and is a result of a successful 2-year long collaboration.
Attana received its first order from the customer in March 2018 and following a successful first collaboration the same customer has since several contract research project.
“We are looking forward to continue working closely with the customer and I see this order as yet another strong validation of our core offering.” – Teodor Aastrup, CEO of Attana, comments.
For more information, please contact:
Niklas Carlsson, COO
+46 (0)73 867 67 62
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in-vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact email@example.com